The drug’s increased demand has resulted in supply disruptions.
The weight loss drug Saxenda (liraglutide) is facing potential shortages through the end of 2023, as reported by the FDA’s Drug Shortages tracker. The increased demand for this GLP-1 receptor agonist, used in chronic weight management for adults and approved for certain pediatric patients, has led to interruptions in supply. Manufacturer Novo Nordisk is actively addressing the situation.
- Saxenda is indicated for chronic weight management in adults with a BMI of 30 kg/m^2 or greater, or 27 kg/m^2 with a weight-related comorbid condition.
- It is also approved for pediatric patients aged 12 and older with body weight above 60kg and an initial BMI corresponding to 30kg/m^2 for adults.
- Increased demand has resulted in supply interruptions, likely to last through 2023.
- Novo Nordisk has established a hotline for patients with questions regarding Saxenda’s availability.
- Wegovy (semaglutide), another weight loss drug by Novo Nordisk, is also on the FDA’s drug shortages list.
- Novo Nordisk has announced legal action against unlawful marketing or sale of products claiming to contain semaglutide, following reports of adverse events.
- The shortage of Saxenda is a significant concern for those relying on this medication for weight management, and the situation is being closely monitored by both the FDA and Novo Nordisk.
Did You Know?
According to a report by the FDA, drug shortages have increased significantly in recent years, with an average of more than 250 new shortages annually between 2015 and 2019.